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ABSTRACT
Background and Objectives: Umbilical port-site infec-
tions after video-laparoscopic cholecystectomy (VLC) are
frequent complications. The aim of this prospective ran-
domized study was to verify the validity of topical rifamy-
cin for prevention of post-VLC umbilical infections.
Methods: From September 2006 to April 2007, 48 patients
with uncomplicated cholelithiasis who underwent VLC
were enrolled in the study. Enrolled patients were ran-
domized into 2 groups. The first group of 24 patients was
treated with topical rifamycin to the umbilicus. The sec-
ond group of 24 patients was not treated with rifamycin.
Results: Postoperative umbilical pain with a need for
analgesics, presence of signs of inflammation of the um-
bilical wound, dehiscence of the umbilical skin sutures,
and the presence of incisional umbilical hernia on the 60th
postoperative day were statistically significantly better in
the rifamycin group compared with the control group.
Conclusions: Topical administration of rifamycin to the
umbilicus in the pre-, intra- and postoperative periods was
a rapid, safe, and economic way to reduce infective com-
plications after VLC.
Key Words: Laparoscopy, Cholecystectomy, Umbilicus,
Rifamycin.
INTRODUCTION
The preoperative preparation of a patient for video-lapa-
roscopic cholecystectomy (VLC) is well defined and in-
cludes short-term antibiotic therapy, prevention of deep
venous thrombosis, and prophylactic cleaning and disin-
fection of the skin.
Open access, during a Hasson video-laparoscopic chole-
cystectomy (VLC) technique, is through the umbilicus.
The umbilicus is an area rich in bacteria, so we thought it
might be useful to use prophylactic topical antibiotic ther-
apy in this region to reduce the incidence of postoperative
infection at the umbilical port site.
Umbilical port-site infection during cholecystectomy is
reported to be 9%1,2 even for a difficult cholecystectomy.3
The role of topical antibiotic prophylaxis is particularly
useful in prevention of local infections in patients with
other major risks, such as immunodeficient patients, patients
taking immunosuppressive drugs, uncompensated diabetic
patients, and others. In the literature, no data show differ-
ences in umbilical port-site infections in the video-cholecys-
tectomized patients who undergo different techniques of
peritoneal access: Hasson, Veress, and others.4,5
The aim of this study was to evaluate the use of topical
prophylactic antibiotic (ie, rifamycin) for prevention of
post-VLC infection at the umbilical port-site.
METHODS
From September 2006 to April 2007, 59 patients with
uncomplicated gallstones underwent VLC, in the Division
of General Surgery, Department of Surgical Sciences of
the University of Foggia, School of Medicine, Polyclinic of
Foggia, Italy. Of these, 48 patients were enrolled in the study:
30 females and 18 males with a mean age of 38 years (range,
21 to 64), affected by the same clinical scenario.
The laparoscopic access technique used was the Hasson
open technique. Rifamycin was chosen as the topical
medication because it is has been used by our institution
for the treatment of local infections with good results.
Rifamycin is usually used topically for the treatment of
infections caused by germs, such as pyodermitis, derma-
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SCIENTIFIC PAPERtitis, skin plagues, abscesses, infected wounds, exposed
trauma, and fistulae, as recommended based on the tech-
nical information about the drug.
We evaluated the results of the topical antibiotic therapy
on a series of patients with no added risk for infection.
Therefore, we excluded from this study patients with
preoperative clinical conditions that might predispose to
the development of port-site infection. Patients with un-
complicated gallstones were enrolled in the study.
The preoperative exclusion criteria were the following: (1)
acute cholecystitis with localized peritonitis; (2) umbilical
hernia; (3) immunodepressed patients; (4) uncompen-
sated diabetes. Four patients with uncompensated diabe-
tes and 2 patients with umbilical hernia were excluded
from the study.
The intraoperative exclusion criteria were the following:
(1) perforation of the gallbladder in the peritoneal cavity
during VLC; (2) perforation of the gallbladder during its
removal through the umbilicus with bile leakage. The
patients who were excluded from the study in the intra-
operative phase were the following: 3 patients with intra-
peritoneal perforations of the gallbladder and 2 patients
with perforations during specimen removal through the
umbilicus.
The enrolled patients were randomized into 2 groups. The
first group (rifamycin group) was treated with rifamycin
(24 patients), and the second group (control group) was
not treated with rifamycin (24 patients).
This protocol aimed at the controls and at the evaluation
only of local infections. So, for all patients, we applied the
usual prophylactic systemic antibiotic protocol used
within our institution by means of the preoperative intrave-
nous administration of2go fceftriaxone, followed by a
second intraoperative dose, and a final dose after 24 hours.
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Figure 1. Umbilical region pain (N24).
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simple procedures in the treatment of the umbilicus dur-
ing the pre-, intra-, and post-VLC phases; the registration
of some objective clinical signs and subjective clinical
symptoms completed the 2 protocol studies.
The protocol for the rifamycin group patients
(rifamycin protocol) had the following phases:
1. Preoperative phase. Twelve hours before VLC, the pa-
tients underwent the following:
a. disinfection of the umbilical and periumbilical skin
with iodopovidone;
b. application of a sterile medication with 3mL of rifa-
mycin (250 mg) on the umbilicus.
2. Intraoperative phase. After gallbladder removal through
the umbilicus, all patients underwent:
a. suture of the umbilical access: muscular fascia and of
the skin wound with Vicryl;
b. disinfection of the umbilical wound and periumbili-
cal skin with iodopovidone first, and then with 0.9%
saline solution;
c. application of a sterile medication with 3mL of rifa-
mycin (250mg) on the umbilical wound.
3. Postoperative phase. At 12, 24, 36, 48, and 72 hours
after VLC, rifamycin was applied in a sterile fashion to the
umbilical wound of all the patients. Evaluation of the
results of the topical antibiotic prophylaxis, in relation to
the development of signs of local infection, was executed
by means of subsequent controls at 12, 24, 36, and 48
hours after VLC and on the third, fourth, fifth, sixth, and
seventh post-VLC day. The evaluated parameters were the
following: (1) umbilical region pain (pain scale from 0 to
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Figure 2. Use of analgesics (N24).
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cal region pain; (3) signs of inflammation of the umbilical
wound (rubor, tumor, calor); (4) purulent leakage through
the umbilical wound; (5) dehiscence of the umbilical skin
sutures. On the 60th post-VLC day, the possible presence
of incisional hernia in the umbilical region was registered.
The protocol for the control group patients (called control
protocol) had the same phases as the above-mentioned
protocol but rifamycin was not one of the pre-, intra-, and
postoperative medications applied. The same surgical
equipment was used to perform the VLC operative tech-
nique in all 48 cases. The data were analyzed using Sta-
tistical Package for Social Sciences software (SPSS version
11.0) by means of the chi-square test.
RESULTS
The topical administration of rifamycin reduced the inci-
dence of omphalitis, a finding that is statistically signifi-
cant. For evaluation of omphalitis, we chose clinical ob-
servation for local signs of inflammation, secretion from
the wound, and dehiscence of cutaneous suture. The
results were reported by means of histograms.
In histogram one (Figure 1), the mean values of the
postoperative observations of pain localized in the umbil-
ical region in patients in both groups are reported
(P0.001). In histogram 2 (Figure 2), the number of
patients in both groups that required added analgesic
drug administration (yes or not) was reported (P0.005).
Histogram 3 (Figure 3) depicts the mean values (on a
scale of 0 to 5) of local signs of inflammation (wound
warmness, hyperemia, umbilical wound swelling) in the
umbilical region in the patients of both groups are re-
ported (P0.001). Histogram 4 (Figure 4) depicts the
number of patients in both groups who suffered purulent
leakage through the umbilical wound (yes or not)
(P0.005). Histogram 5 (Figure 5) depicts the number of
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Figure 3. Signs of phlogosis of the umbilical wound (N24).
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bilical skin sutures (yes or no) (P0.001).
Clinical data were registered at 12, 24, 36, and 48 hours
after the VLC and also on the third, fourth, fifth, sixth, and
seventh post-VLC day; for the patients dismissed before
the third postoperative day, there was an ambulatory
outpatient control.
Sixty days after VLC, 2 cases of incisional umbilical
hernias were reported in the control group.
The mean postoperative stay was 3 days in the rifamycin
group (range, 1 to 8), and 4 days in the control group
(range, 3 to 8).
DISCUSSION
Omphalitis is a minor postoperative complication after
VLC. It is treated quite simply as an outpatient problem,
but omphalitis represents discomfort for the patient, and it
can cause a delay in the resumption of work. But, above
all, omphalitis is a risk factor for the development of
incisional umbilical hernia, which may occur in greater
than 1% of cases.6
Postoperative umbilical port-site infection after VLC is a
factor in the morbidity of this procedure, as it requires
twice as much outpatient observation and treatment.
The occurrence of problems that were statistically signif-
icant (P0.001) included referred pain of the umbilical
region, local development of the classical signs of inflam-
mation (rubor, tumor, calor, and others), and dehiscence
of the cutaneous suture.
Our results show that in patients treated with rifamycin,
umbilical port-site infections occurred less often than in
the control group. Even analgesic usage and purulent
secretion from the umbilical wound were statistically dif-
0
5
10
15
20
25
Hr 12 Hr 24 Hr 36 Hr 48 Day 3 Day 4 Day 5 Day 6 Day 7
Postoperative Time
N
o
.
 
o
f
 
P
a
t
i
e
n
t
s
Control Group Rifamycin Group
Figure 4. Umbilical wound leakage (N24).
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group.
On the whole, a graphic representation of the results
depicts a statistically significant difference between the 2
groups of patients, in favor of the rifamycin group. Topical
prophylactic antibiotic therapy reduces omphalitis.
Moreover, control of the umbilical port-site infections is a
relevant element in the patients with metabolic diseases
and/or with alterations of the immune system, because
they are frequently exposed to infections.
Systemic prophylactic antibiotic therapy in VLC maintains
its usual role.7,8 Topical antibiotic prophylaxis was effica-
cious in reducing infections, but its use is not meant to
replace systemic antibiotic prophylaxis. Rather, its use is
to serve as an adjunct to systemic antibiotic prophylaxis so
that the usual antibiotic protocol is not changed (ie, short-
and ultra short-term antibiotic therapy).
The main result of this study is that umbilical port-site
infections can be reduced by the topical use of rifamycin.
In addition, patient comfort was enhanced in the rifamy-
cin group compared with the control group.
Patients in the rifamycin group had minor postoperative
morbidity caused by the presence of omphalitis, shorter
postoperative stay, and almost no need of outpatient am-
bulatory medications.
The cost of the use of rifamycin in the pre-, intra-, and
post-VLC period is surely less than is required for the
ambulatory treatment of a postoperative wound infection.
The reduction of omphalitis with topical prophylactic an-
tibiotic therapy is cost effective. Patients can resume work
sooner, and ambulatory management requires less com-
mitment in terms of human resources (physicians, nurses)
and medical materials.
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Figure 5. Umbilical skin suture dehiscence (N24).
JSLS (2008)12:126–132 131The literature reports the use of several methods to reduce
the incidence of post-VLC umbilical port-site infections,
such as specimen removal by means of an endo-bag,7 but
in no study is the topical utilization of an antibiotic (like
rifamycin) described during the pre-, intra-, and post-VLC
periods.
The advantages derived from the use of rifamycin are
significant, even if they are for a minor postoperative
complication.
CONCLUSION
In this study, we examined a simple, economic way to
treat the umbilicus to significantly reduce the incidence of
post-VLC omphalitis. The data gathered showed positive
and statistically significant results in favor of the rifamycin
group. The series of patients, however, was limited and
further studies are encouraged. Based on the above, use
of topical rifamycin on the umbilicus is proposed as a
rapid, safe, and economic way to reduce postoperative
morbidity following VLC.
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